The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta

SIMPLE SUMMARY: Since IL-2 co-treatment did not show any therapeutic benefit in the GD(2)-directed treatment of high-risk neuroblastoma (NB) but strongly induced regulatory T cells (Treg), we investigated here the immunocytokine FAP-IL-2v stimulating NK and cytotoxic T cells without induction of Tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Siebert, Nikolai, Leopold, Justus, Zumpe, Maxi, Troschke-Meurer, Sascha, Biskupski, Simon, Zikoridse, Alexander, Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563425/
https://www.ncbi.nlm.nih.gov/pubmed/36230765
http://dx.doi.org/10.3390/cancers14194842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563425/
https://www.ncbi.nlm.nih.gov/pubmed/36230765
http://dx.doi.org/10.3390/cancers14194842

Ejemplares similares